Acumen Pharmaceuticals, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Acumen Pharmaceuticals, Inc. (ABOS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $2.11 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- Acumen Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $3.77, a 25.67% increase year-over-year.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $3.00.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2022-03-31 was $1.19.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $2.75, a 52.26% decline from fiscal 2024.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $5.76, a 100.00% increase from fiscal 2023.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $2.88, a 54.65% decline from fiscal 2022.
- Acumen Pharmaceuticals, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $6.35.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.11 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $3.77 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $2.75 10-K · filed 2026-03-26 | |||
| 2025-09-30 | $2.75 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $2.64 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $3.00 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | $5.76 10-K · filed 2025-03-27 | |||
| 2024-09-30 | $7.36 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $7.36 10-Q · filed 2024-08-13 | |||
| 2023-12-31 | $2.88 10-K · filed 2024-03-26 | |||
| 2023-09-30 | $2.88 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $3.23 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | $6.35 10-K · filed 2023-03-27 | |||
| 2022-09-30 | $6.35 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $2.11 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | $1.19 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |